Bacteria over-expressing c-di-AMP and therapeutic methods
US10130663B2 · kind B2 · utility
2Cited by
7References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 10, 2016 |
| Grant date | Nov 20, 2018 |
| Priority date | — |
| Expiry date | Feb 10, 2036 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/522
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention includes the discovery of a strain of Mycobacterium comprising an expression vector encoding a di-adenylate cyclase enzyme. The Mycobacterium is selected from the group consisting of Mycobacterium tuberculosis, Mycobacterium bovis, or a combination thereof and the preferred strain of Mycobacterium is BCG. The preferred expression vector is a mycobacterial expression vector including an hsp60 promoter and a DNA sequence of diadenylate cyclase (disA), or a functional part thereof. The strains of Mycobacterium are used in therapeutic applications including tuberculosis and cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.